Pacific Biosciences of California, Inc. filings document operating results, governance changes, material agreements, and asset-disposition activity tied to its sequencing business. Recent Form 8-K reports furnish quarterly and full-year financial results, business updates, revenue categories for instruments, consumables, and services, and disclosures related to the company’s long-read sequencing focus.
The filing record also includes proxy materials covering board structure, director elections, executive compensation, equity awards, and stockholder voting matters. Other 8-K disclosures address board appointments, changes in accounting-officer responsibilities, operating responsibility assignments, intellectual-property arrangements, and the completed sale of assets related to short-read DNA sequencing technology.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer Christian O. Henry reported an open-market sale of 12,497 shares of common stock at a weighted average price of $1.514 per share, in transactions ranging from $1.49 to $1.56, to cover tax withholding on vested restricted stock units. After these tax-related sales, he directly held 3,581,813 shares of PACB common stock.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer Mark Van Oene reported an open-market sale of 6,504 shares of common stock at a weighted average price of $1.514 per share. The shares were mandatorily sold to cover tax withholding obligations from vesting restricted stock units, leaving him with 2,243,634 shares held directly.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer Michele Farmer reported an automatic sale of common stock tied to tax withholding. On this Form 4, 2,979 shares were mandatorily sold to cover tax obligations from vesting restricted stock units at a weighted average price of $1.514 per share. After this tax-related transaction, Farmer directly held 305,948 shares of PACB common stock.
Pacific Biosciences of California, Inc. reported that officer Michele Farmer received new equity awards. On February 27, 2026, Farmer was granted a stock option covering 179,670 shares of common stock at an exercise price of $0.00 per share, and an award of 89,835 shares of common stock at $0.00 per share.
The 89,835-share award is in the form of Restricted Stock Units that vest in three equal annual installments on February 15, 2027, 2028, and 2029, if Farmer continues as a service provider. The option vests in 36 equal monthly installments beginning March 27, 2026, also conditioned on continued service.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported that executive James R. Gibson II received new equity awards. He was granted a stock option for 667,696 shares with an exercise price of $0.00 per share, and 333,848 shares of common stock as restricted stock units.
The RSUs will vest in equal annual installments on February 15 of 2027, 2028, and 2029, subject to his continued service. The stock option will vest in 36 equal monthly installments beginning on March 27, 2026, also conditioned on continued service. These are non-cash, compensation-related acquisitions rather than open-market purchases.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported that company officer Mark Van Oene acquired new equity awards. He received a stock option for 1,000,000 shares at an exercise price of $0.00 per share and a grant of 500,000 shares of common stock.
The 500,000 shares are in the form of Restricted Stock Units that vest in three equal annual installments on February 15, 2027, 2028, and 2029, contingent on continued service. The 1,000,000-share option vests in 36 equal monthly installments beginning on March 27, 2026, also subject to his continued status as a service provider.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported that officer Christian O. Henry received equity-based compensation on February 27, 2026. He was granted a stock option for 1,841,621 shares at an exercise price of $0.00 and 920,810 shares of common stock represented by restricted stock units.
The option vests in 36 equal monthly installments beginning on March 27, 2026, while the RSUs vest in three equal annual installments each February 15 of 2027, 2028, and 2029, in both cases requiring his continued service to the company.
Mark Van Oene reported sales of Common stock. The filing lists two transactions: 02/17/2026 sale of 129,790 shares for $204,549.04 and 02/18/2026 sale of 55,107 shares for $89,769.30. The filing also lists Restricted Stock to be sold on 03/02/2026.
Christian Henry reported sales of PACB common stock. The filing shows dispositions of 331,793 shares on 02/17/2026 and 140,874 shares on 02/18/2026, with proceeds listed as $522,905.77 and $229,483.75, respectively.
The transactions are reported on Form 144 and reflect restricted-stock sales by an issuer-side holder; timing and amounts are stated in the filing.
Pacific Biosciences of California, Inc. filed a Form S-3 shelf registration dated February 25, 2026 that permits the company to offer, from time to time, common stock, preferred stock, depositary shares, debt securities, warrants, subscription rights, purchase contracts and units. The filing also covers possible resales by selling stockholders; the company will not receive proceeds from resale transactions by those selling stockholders.
The prospectus describes general terms and distribution methods and states that specific offering amounts, prices, terms and expected net proceeds (when applicable) will be provided in prospectus supplements. The company’s common stock trades on Nasdaq under the symbol PACB.